Cadila Healthcare announces tentative approval for Glipizide ER tablets

From USFDA

Cadila Healthcare announced that Zydus Cadila has received tentative approval from US FDA to market Glipizide Extended Release tablets in the strengths of 2.5 mg, 5 mg and 10 mg. The drug falls in the ant-diabetic segment.

The estimated sales in 2014 for Glipizide Extended Release tablets is USD 90.1 million, as per IMS.

Powered by Capital Market - Live News